The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Researchers from King's College London have called for urgent changes to the way new antibiotics are developed to address the ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID ...

WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday unveiled the names of the eight new members who will sit on ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

(Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach ...

Pfizer Inc. plans to spend billions of dollars to join the race for a new type of cancer treatment. Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...